Findings are from a large-scale cohort study in the Netherlands.
-
Increasing parity with ART is linked to reduced ovarian cancer risk -
Recurrent ovarian cancer: good response with pembrolizumab, bevacizumab-cyclophosphamide combo The combination was well tolerated in a phase 2 cohort study.
-
Findings suggest that outcomes might be improved with targeted physical activity and exercise recommendations.
-
Ovarian cancer: maintenance niraparib delays progression Individualized niraparib dosing is effective and safe.
-
Diabetes is linked to a higher incidence of ovarian cancer Results are from a meta-analysis of 36 studies.
-
Advanced ovarian cancer: do not deny surgery after NACT based on objective responses Standalone RECIST or CA125 should not be considered for patient selection for surgery.
-
Ovarian cancer: maintenance vaccine fails primary endpoint Further investigation in patients with BRCA-mutated disease is warranted.
-
Gynecologic cancers: adherence to oral agents remains subpar Findings from a cross-sectional survey and qualitative interviews.
-
Recurrent ovarian cancer: 3-drug combo shows good response Pembrolizumab-bevacizumab-cyclophosphamide were well tolerated.
-
Ovarian cancer: Tie-2 is a prognostic factor Angiopoietin-2 and Tie-2 expression is increased with distal omental metastasis.
-
Advanced ovarian cancer: conservative treatment allows for spontaneous pregnancy but with high recurrence rate Patient should be informed of high risk for recurrence while proposing conservative treatment.
-
Selinexor shows activity in ovarian and endometrial cancers All 4 administered regimens elicited a response.
-
Ribociclib-letrozole combo shows promise in ER+ ovarian, endometrial cancer Patients with ER+ recurrent low-grade serous ovarian cancer derive most benefit.
-
Ovarian cancer: NACT use has increased despite no clear OS benefit Study supports treatment individualization based on patient and tumor factors.